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Abstract Stromal vascular fraction (SVF), an adipose
tissue-derived heterogeneous cell mixture containing,
among others, multipotent adipose stromal cells (ASCs)
and erythrocytes, has proved beneficial for a wide range of
applications in regenerative medicine. We sought to
establish intervertebral disc (IVD) regeneration by inject-
ing SVF intradiscally during a one-step surgical procedure
in an enzymatically (Chondroitinase ABC; cABC) induced
goat model of disc degeneration. Unexpectedly, we ob-
served a severe inflammatory response that has not been
described before, including massive lymphocyte infiltra-
tion, neovascularisation and endplate destruction. A second
study investigated two main suspects for these adverse
effects: cABC and erythrocytes within SVF. The same
destructive response was observed in healthy goat discs
injected with SVF, thereby eliminating cABC as a cause.
Density gradient removal of erythrocytes and ASCs puri-
fied by culturing did not lead to adverse effects. Following
these observations, we incorporated an extra washing step
in the SVF harvesting protocol. In a third study, we applied
this protocol in a one-step procedure to a goat herniation
model, in which no adverse responses were observed
either. However, upon intradiscal injection of an identically
processed SVF mixture into our goat IVD degeneration
model during a fourth study, the adverse effects surpris-
ingly occurred again. Despite our quest for the responsible
agent, we eventually could not identify the mechanism
through which the observed destructive responses oc-
curred. Although we cannot exclude that the adverse ef-
fects are species-dependent or model-specific, we advertise
caution with the clinical application of autologous SVF
injections into the IVD until the responsible agent(s) are
identified.
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Introduction
A comprehensive number of diseases and degenerative
conditions have recently been treated successfully with
stromal vascular fraction (SVF), a mixture of various cell
types derived from adipose tissue. Besides multipotent
stromal cells, this heterogeneous cell mixture has been
reported to contain endothelial cells, pericytes and he-
matopoietic cells (monocytes, lymphocytes and granulo-
cytes) [1] (Table 1). Also, large numbers of erythrocytes
are present in this mixture, despite several washing steps
(108–109 cells per ml compared to 5 9 109 erythrocytes
per ml whole blood). In addition to soft tissue applications
such as pulmonary fibrosis [2] and vascular bypasses [3]
that have benefited from the healing potential, muscu-
loskeletal research groups have successfully incorporated
SVF in their therapies, like for chondromalacia patellae [4].
Correspondingly, our group had thriving experiences with
this cell mixture, as demonstrated in goat osteochondral
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defects [5] and a clinical trial for maxillary sinus floor
reconstruction [6]. As a result, the general idea has
emerged that autologous SVF could be safely and effec-
tively applied to address a miscellaneous set of disorders.
The focus of our group lies on the treatment of inter-
vertebral disc degeneration, a relevant clinical condition
because of its reported correlation to low back pain [7]. To
investigate disc degeneration in a reproducible fashion, a
goat model was developed using a low dose of Chon-
droitinase ABC [8, 9]. This enzyme had been reported
before as a method to lower intradiscal pressure by
cleaving proteoglycans in high doses (1–50 units) [10, 11]
and, in addition, to start mild disc degeneration in lower
doses (0.25 units/ml) in several animal models [12, 13].
Next, we formulated a new concept in which adipose stem
cells were harvested and reinserted in a single session for
intervertebral disc degeneration, similar to a previously
described one-step surgical procedures for other applica-
tions (Fig. 1) [5, 14, 15]. In this one-step procedure, adi-
pose tissue is enzymatically digested, centrifuged and
washed to obtain a heterogeneous mixture of cells, called
the stromal vascular fraction (SVF). This fraction was in-
jected in goat intervertebral discs, both in healthy IVDs and
in discs that had been altered either by chemical degen-
eration using CABC or surgical nucleotomy.
Unexpectedly, in three out of four consecutive studies
designed to evaluate the regenerative potential of SVF, we
observed severe adverse events in a substantial number of
discs that had been injected with autologous SVF. Infil-
tration with inflammatory cells was observed in the nucleus
pulposus, as well as local destruction of the gross anatomy.
In our search for an explanation for these adverse events,
we have ruled out several potential mechanisms through
which these adverse events could have occurred. Despite
efforts to systematically investigate the responsible etio-
logical factor for these adverse effects, the underlying
mechanism has not yet been entirely elucidated.
Nevertheless, we want to share our experience with the
research community and conclude that intradiscal therapies
containing autologous SVF do not appear ready for appli-
cation in clinical practice. Here, we present our observa-
tions after four studies in a goat model on the effects of
autologous SVF in the IVD and report our efforts to
identify the cause of the observed adverse events.
Experiments
First study: stromal vascular fraction injection
after chemical disc degeneration
A total of twelve female adult Dutch milk goats underwent
a surgical procedure to induce disc degeneration by in-
jecting five lumbar discs through a left retroperitoneal ap-
proach with 0.25 U/ml Chondroitinase ABC (CABC;
Sigma, St. Louis, MO, USA) as described before [8]. Disc
degeneration was allowed to develop for 3 months, after
which this study was designed as a time-oriented study.
During the second surgical procedure,*100 g of perirenal
adipose tissue was harvested and SVF was isolated as de-
scribed by Zuk et al. [16] with minor modifications. The
obtained adipose tissue was washed with phosphate-buf-
fered saline (PBS) to remove the majority of red blood
cells, chopped into small pieces of about 50 mm3, and the
extracellular matrix was digested for 60 min at 37 C with
1 U of collagenase (‘‘Blendzyme’’, Roche Diagnostics,
Brussels, Belgium) per gram adipose tissue in PBS. A
single cell suspension was obtained by filtering the di-
gested material through a 100-lm mesh filter (Stokvis and
Smith B.V., IJmuiden, The Netherlands) to remove tissue
debris. The adipose stem cell-containing cell suspension
was centrifuged at 600g for 10 min, and the pellet was
resuspended in culture medium, which was composed of
Dulbecco’s modified eagle medium (DMEM, Gibco,
Paisley, UK), supplemented with 500 lg/ml streptomycin
sulphate (Sigma), 600 lg/ml penicillin (Sigma), 50 lg/ml
gentamicin (Gibco), 2.5 lg/ml fungizone (Gibco), and
10 % foetal bovine serum (FBS, Hyclone, Logan, UT).
After centrifugation, the SVF pellet was resuspended in
DMEM without additives, washed for an additional two
times with PBS, and subsequently resuspended to either
106 or 107 cells/ml PBS. In each goat, four degenerated
discs were injected with 100 ll containing either 105 or 106
freshly isolated nucleated cells or plain PBS as a control
treatment, in a randomised fashion, using a 26-Gauge
needle. After wound closure, the animals were allowed to
move freely with follow-up periods of 1 (n = 7) and
3 months (n = 5). Prior to killing, goats were sedated with
10 mg/kg ketamine intramuscularly, and lateral radio-
graphs were obtained. Subsequently, they were euthanised
Table 1 Composition of adipose-derived stromal vascular fraction
(SVF) according to the International Federation for Adipose
Therapeutics and Science (IFATS) and International Society for
Cellular Therapy (ISCT)
Cell populations resident in SVF (%)
Hematopoietic-lineage cells







Table obtained from [1]
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with an intravenous overdose of sodium pentobarbital
(20 mg/kg), after which the lumbar spines were harvested,
dissected and prepared for further analysis.
Histologically, the intervertebral discs used as sham
controls had a normal appearance with concentric annular
lamellae, which were easily distinguishable from the nu-
cleus pulposus tissue (Fig. 2a). The extracellular matrix of
the latter had an open structure with chondrocyte-like cells
present in the matrix. The enzymatically degenerated discs
injected with PBS in the second surgery (sham treatment)
had a more degenerated appearance (Fig. 2b). In these
discs, annular fissures were observed, as well as a con-
densation of the extracellular matrix of the nucleus pul-
posus with a decreased number of cells and a diminished
demarcation between annulus fibrosus and nucleus pulpo-
sus (Fig. 2b). In 38 of 48 of the discs injected with SVF
fraction, a severe inflammatory response occurred
(Fig. 2c). Ten out of 14 discs injected with 105 perirenal
SVF demonstrated an inflammatory response and the same
was observed in 13/14 discs injected with 106 cells after
1 month. After three months, this response was observed in
7/10 and 8/10, respectively. In the central region a cellular
infiltrate, mainly consisting of plasma cells and macro-
phages, was observed in the early phase (1 month) of the
response (Fig. 2d). At the margins, neovascularisation was
observed in the disc and osteoclastic activity was high
at the bone–infiltrate junction (Fig. 2e). After three
months, (myo)fibroblastic cells were observed in the
central area where extensive remodelling (scar tissue
formation/collagen deposition) occurred. This reaction was
similar to the response that was observed in discs injured
with higher doses of Chondroitinase ABC [8]. Also, os-
teoblasts were found at the margins rimming along osteoid.
Simultaneously, we conducted a similar pilot study, using
hyaluronic acid as a vehicle, in which we observed the
same response and adverse effects (data not shown).
After this first regeneration study using autologous SVF
in a goat model, two hypotheses were formulated as po-
tential causes of the observed inflammatory response. First,
residual enzyme activity of Chondroitinase ABC was
suggested as a possible culprit for the adverse effects. Se-
cond, the reaction might have stemmed from the presence
of macrophages in combination with red blood cells
(RBCs) in the cell mixture. After all, RBCs had previously
been reported to induce cartilage damage in the joints of
haemophilia patients, resulting in haemophilic arthropathy
by the iron-catalysed production of destructive oxygen
metabolites [17]. To determine the trigger for the inflam-
matory response in our first study, an additional study was
designed, in which the goal was threefold: (1) to rule out
that adverse effects had been due to residual CABC ac-
tivity, (2) to exclude the large number of RBCs as causing
mechanism and (3) to investigate a more homogeneous
stem cell fraction. For the first purpose, SVF was also in-
jected into healthy goat discs; for the second goal, SVF was
treated with a density gradient (Optiprep) to get rid of the
RBCs; and third, adipose-derived stem cells (ASCs) were
cultured before implantation in goat IVDs.
Fig. 1 Concept of a one-step
surgical procedure. The surgery
starts with harvesting of the
adipose tissue, followed by a
split procedure. The surgeon
continues the surgery, while the
tissue engineer isolates the stem
cell-containing cell population
from the adipose tissue, treats
the cells to induce
differentiation into the proper
phenotype (optional), and seeds
the stimulated cells on the
scaffold. The surgeon then
implants the scaffold containing
the stem cells, and finishes the
surgery. The whole procedure
takes approximately 2 h
1994 Eur Spine J (2015) 24:1992–2000
123
Fig. 2 a Micrograph of a paramidsagittal section of a sham-operated
disc stained with AB-PAS. The disc was isolated after 1 month (91).
There is a normal, concentric organisation of the lamellae of the
annulus fibrosus (AF), the extracellular matrix (ECM) of the nucleus
pulposus (NP) is proteoglycan-rich and the border between the NP
and the AF is easily recognisable. b Micrograph of a paramidsagittal
section of a PBS-injected disc stained with AB-PAS. The disc was
collected after 1 month (91). This disc shows some characteristics of
mild disc degeneration: the border between the NP and AF is not well
defined, the ECM of the NP is denser and cracks are visible in the AF.
c Micrograph of a paramidsagittal section of a stromal vascular
fraction (SVF; 106 nucleated cells/ml) injected disc stained with
AB-PAS. Disc was collected after 1 month (91). The inflamed area in
the NP extends into the vertebral bodies, through both endplates.
Also, beginning osteophyte formation can be observed. The grey box
position of micrograph d, the white box of micrograph e. d Detail of a
SVF (106 nucleated cells/ml) injected disc stained with AB-PAS after
1 month (9200). This micrograph is a detail of the round cellular
infiltrate observed in the 1-month follow-up group after injection of
the disc with SVF. e Detail of a SVF (106 nucleated cells/ml) injected
disc stained with AB-PAS after 1 month (9200). This detail shows
two osteoclasts as observed at the edges of the inflammatory response
and the vertebral bodies
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Second study: healthy discs, red blood cell depletion
and cultured adipose-derived stem cells
To rule out that adverse effects were due to residual CABC
activity (after 3 months incubation time to develop de-
generation), one healthy disc in each of six goats was in-
jected with SVF. Furthermore, plain SVF, density gradient-
treated SVF and cultured ASCs were randomly evaluated
in four chemically degenerated discs, using the same goat
intervertebral disc degeneration model as in the first study.
For the two SVF groups (plain SVF and density gradient-
treated SVF), the same protocol was followed in this sec-
ond study for the harvesting of SVF. After re-suspension in
DMEM without additives, the SVF was divided into two
equal parts. One part was further processed as described for
the first study (plain autologous SVF), whereas the other
part was subjected to Optiprep density gradient centrifu-
gation. Optiprep density gradient-mediated SVF purifi-
cation through reduction of red blood cells (RBCs) was
performed according to the manufacturer’s instructions
(protocol C2, Axis-shield). The mononuclear stromal vas-
cular fraction band was collected, washed twice with PBS,
and finally resuspended to 106 nucleated cells/ml in PBS.
Of this cell suspension, 100 ll was injected in the enzy-
matically degenerated discs. For the cultured ASCs group,
adipose tissue had already been harvested during the de-
generation induction surgery, and these cells were resus-
pended in culture medium and seeded in 75 cm2 culture
flasks (Greiner Bio-One, Kremsmuenster, Austria). Upon
confluency, adipose-derived stem cells (ASCs) were tryp-
sinised from the culture flasks using 0.25 % trypsin/0.1 %
EDTA in PBS, harvested, and reseeded once (passage 1).
After harvesting, cells were stored in liquid nitrogen until
one week before reinsertion. At that time, cells were
thawed, allowed to recover for one week, and finally re-
suspended to 106 nucleated cells/ml PBS just prior to im-
plantation in the goat discs.
Both the healthy and the previously degenerated discs
injected with plain SVF exhibited an inflammatory response
similar to those described in the first study. We observed
scar tissue formation in the central part of the nucleus
pulposus and bone formation at the rims of the vertebrae.
Discs injected with RBC-depleted SVF (Optiprep) demon-
strated mild degeneration, although one disc out of six re-
vealed similar endplate irregularities and an inflammatory
response as described in the plain SVF-injected discs.
CABC-degenerated discs injected with PBS showed iden-
tical results to discs injected with cultured ASCs, i.e. no
inflammatory response or endplate irregularities in any disc,
thus ASCs themselves showed no adverse effects at all. A
regenerative response could not be identified in these discs
either, although some discs did show increased numbers of
nucleus pulposus-like cells [18].
This second study attempted to pinpoint the cause of the
adverse events by applying (a) density gradient removal of
RBCs; (b) ASCs cultured to homogeneity (to remove RBCs
as well as other contaminating cell types present in SVF);
and (c) injection of SVF in intact discs to rule out CABC-
mediated effects. It was concluded that RBCs indeed might
have been the cause of the adverse effects and that the
adverse effects were not due to the CABC that was used to
create the degenerative disc model. Furthermore, we con-
cluded that cultured ASCs did not regenerate the disc after
mild degeneration, but neither did this treatment lead to
adverse effects. In contrast, a similar experiment had been
performed in a canine model, in which none of these ad-
verse events were described [19]. This led us to the for-
mulation of several other potential causes for the adverse
events observed in our first two studies, based on the dif-
ferences between our studies and the dog study, namely
(a) residual collagenase activities in the SVF mixture;
(b) the enzymatically induced disc degeneration, in con-
trast with the herniation model used in the referred study;
(c) specific interaction based on the goat species used; and
(d) potential cell mixture differences due to the harvest
location of the adipose tissue. To investigate these newly
formulated hypotheses, a third goat study was conducted.
Third study: partial nucleotomy model
During the first surgical procedure, the nucleus pulposus
from three (n = 2 goats) or four (n = 2 goats) disc levels
(randomly between T13–L1 and L5–L6) were partially
excised under open surgical dissection. The annulus fi-
brosus was allowed to heal for approximately six weeks
prior to disc therapy. In the second procedure, adipose
tissue was harvested from both the perirenal area and a
subcutaneous site, and transferred to a cell processor.
Adipose tissue was weighed, transferred to tissue culture
grade plastic dishes, and minced finely with scissors and/or
scalpels under sterile conditions. The minced tissue was
then washed with warmed Lactated Ringers, after which 1
U/ml collagenase (CELASETM, Cytori Therapeutics Inc,
San Diego, CA, USA) was added to the tissue. After ap-
proximately 50 min of digestion, the digested tissue was
further washed and concentrated, by spinning. One addi-
tional washing step was added in comparison with the
protocol of the first two studies to further minimise residual
enzyme activity. Under fluoroscopic visualisation, the ap-
propriate test material was applied through a right-lateral
approach by injection with a 25-Gauge needle into the
appropriate level as described before. The nucleotomised
IVDs received 100–200 ll of hyaluronic acid vehicle
mixed with either 2 9 106 nucleated cells/ml isolated from
perirenal fat (perirenal SVF), 2 9 106 nucleated cells/ml
isolated from subcutaneous fat (subcutaneous SVF) or
1996 Eur Spine J (2015) 24:1992–2000
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hyaluronic acid vehicle with PBS (sham control) in a
randomised fashion. The intact discs received 0.1 ml of 107
nucleated cells/ml isolated from perirenal fat, 107 nucle-
ated cells/ml isolated from subcutaneous fat or PBS in a
randomised fashion. In total, 24 discs were involved in the
experiment; the follow-up period was four weeks. In par-
allel to the animal study, characterisation of SVF from the
different sources was performed including red blood cell
counts, determination of ASC colony frequency and ana-
lysis of residual enzyme activity in the last PBS washing
step, using caseinolytic and gelatinolytic assays.
The histological results of this third study were
promising as the discs looked largely unaffected by the
injection of different treatment groups. Annulus layers
were still outwardly folded, no inflammatory responses, no
increased cellularity, and no apparent differences between
the groups were observed. Red blood cell numbers were
108–109 cells per ml SVF and residual enzyme levels were
negligibly low or even below assay baseline threshold.
After the successful elimination of adverse events in the
third goat study, we concluded that adding an extra
washing step to the SVF harvesting protocol had
eliminated the adverse events. Furthermore, subcutaneous
adipose tissue appeared to yield a higher number of ASCs
per ml SVF obtained and showed similar values as de-
scribed for human SVF. Therefore, in the next study design
for disc regeneration, the subcutaneous harvest location
was used.
Fourth study: stromal vascular fraction and bone
morphogenetic protein-2
This study was performed in the context of a disc regen-
eration study using a newly developed hyaluronic acid-
fibrinogen hydrogel (ratio 1:18 w/w, MW 235 kDa, Pro-
Core Bio Med Ltd, Ness Ziona, Israel) and BMP-2
(200 ng/ml, UHZ, Zu¨rich, Switzerland). In seven adult
Dutch milk goats, five lumbar IVDs were chemically de-
generated during 3 months using 0.25 U/ml Chondroiti-
nase ABC. During the second procedure, subcutaneous
adipose tissue was harvested and SVF was isolated, fol-
lowing the same protocol as described before in the pre-
vious studies. Subsequently IVDs were randomised to five
intervention groups: hyaluronic acid-fibrinogen vehicle
only, vehicle with SVF (106 nucleated cells), vehicle with
BMP-2, vehicle with both SVF and BMP-2 or no inter-
vention. After killing at 3 months follow-up, lumbar spines
were harvested for further analysis, using lateral radio-
graphs, T2-weighted MRI, macroscopic and histological
scoring.
This fourth study demonstrated once more an inflam-
matory response in 83 % of the discs injected with au-
tologous SVF, concurrent with severe degenerative
changes in all parameters. Figure 3 shows typical examples
of osteophyte formation (3a) and endplate destruction (3b)
on lumbar radiographs, as well as a complete loss of
morphological organisation on T2-weighted MRI (3c).
Nota bene: on the MRI images, the apophyses adjacent to
the endplates are still visible, as in adult goats the growth
plates persist after skeletal maturity [20]. No adverse ef-
fects were observed after injection of the hydrogel alone or
in combination with BMP-2 into the mildly degenerated
IVDs. In particular, no osteophytes were present in the
group injected with vehicle and BMP-2 only.
Macroscopically, massive scarring was observed in the
SVF-injected IVDs, including endplate destruction and
osteophyte formation (Fig. 4). On histological sections,
scar formation, endplate destruction and inflammatory
cells, including macrophages and plasma cells were ob-
served, indicating a chronic inflammatory response. Also,
neovascularisation was observed in the discs as well as
osteoclasts at the interface between NP and endplates. We
saw no signs of infection, such as microorganisms, neu-
trophil or eosinophil granulocytes. Healthy discs were
characterised by a well-defined demarcation between the
NP and AF, organised collagen fibres and a normal ge-
latinous appearance of the NP matrix.
Discussion
The goal of our studies was to achieve regeneration of the
intervertebral disc in a validated goat model of disc de-
generation using a one-step surgical procedure with adi-
pose-derived SVF, a heterogeneous cell mixture that has
been recognised for its healing potential in various de-
generative conditions. This paper primarily describes our
consistent observations of a severe inflammatory response
to autologous SVF injections in goat discs after prior en-
zymatically induced degeneration. Despite our efforts to
identify the responsible etiological factor for these adverse
effects, a watertight explanation for these effects did not
emerge.
Several factors, however, have been ruled out by the
combination of these studies. First, we refuted infection as
a possible cause because of the absence of microorganisms,
neutrophil and eosinophil granulocytes in histological
sections. All goats were closely monitored and did not
show any sign of infection, nor were there any microor-
ganisms found in SVF cultures. With the second study, we
showed that the adverse events were not caused by CABC,
because the response also occurred after SVF injection in
healthy discs. Also, residual collagenase activity was
probably not the cause, as measured enzyme levels were
very low in the third study. Furthermore, cell numbers per
se seemed unlikely, as the same number of cultured
Eur Spine J (2015) 24:1992–2000 1997
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adipose-derived stem cells did not show adverse effects.
Overall, we excluded infection and residual enzyme ac-
tivity (both CABC and collagenase) as potential causing
factors as well as showing that BMP-2 did not contribute to
the adverse reaction. Finally, our experience with SVF has
not been limited only to IVD studies, but encompasses
successful application of this heterogeneous cell mixture in
knee osteochondral defects, spinal fusion, and a phase I
clinical trial on the use of SVF in maxillary sinus recon-
struction [5, 6, 21]. These successes reject laboratory- or
goat-related problems or fat harvest location as a possible
culprit for the observed detrimental effects and render is-
sues with remaining enzyme levels implausible.
Various other factors that may have contributed to the
adverse effects were discussed within our group. As
highlighted in the previous paragraph, injecting a large
number of cells into the intervertebral disc, the largest
avascular structure in the body could be considered a factor
of influence. This hypothesis was substantiated by the ob-
servation in our first study, in which 105 or 106 nucleated
cells were injected, the latter performing worse. Cultured
adipose-derived stem cells injected in the same numbers,
however, did not show adverse effects. On the other hand,
the heterogeneous SVF cell population can only to a certain
extent be compared with cultured ASCs, because it con-
tains quite different cell types. We could speculate on the
difference in cell survival within SVF: we assume that the
haematopoietic and endothelial cells have a shorter lifetime
in the IVD than the more robust ASCs; this would lead to
more cell death in the SVF groups, which could evoke
invasion of pro-inflammatory cells. ASCs, being multipo-
tent cells, are more adaptive to the environment and may
therefore stand a better chance in the harsh circumstances
in the disc. Alternatively, the high shear rates when passing
through a thin needle could influence the survival of var-
ious cell types differently, possibly favouring the ASCs. To
rule out this theory, we checked the survival of ASCs in
SVF after passing through a thin needle, after which we
saw no differences compared to control (data not shown).
As a second hypothesis, the very high pressures involved
in the injection of substantial volumes into the IVDs were
considered. Mao et al. [22] described adverse effects fol-
lowing the injection of large volumes of PBS into rat tail
IVDs. However, the volumes they injected (up to 3 ll)
equaled the total nucleus volume of rat discs (3.10 ll),
whereas we only injected up to one-fifth of total nucleus
volume (max. 200 ll into 1,000 ll). Moreover, the lack of
degenerative signs in IVD levels injected with similar
Fig. 3 a Lumbar spine
radiograph of osteophytes
forming a bony bridge on the
ventral side of an affected
intervertebral disc. b Lumbar
spine radiograph showing
destruction of the bony
endplates. c T2-weighted MRI
of the lumbar spine in which the
middle IVD has lost its normal
morphological organisation.
Left IVD is a normal control;
right had some calcification in
the centre of the nucleus
pulposus
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volumes of both non-cell-containing solutions and cultured
ASCs rejects this hypothesis. However, a combined effect
of injected cells and high intradiscal pressure, for instance,
by the influx of inflammatory cells through generated mi-
cro-damage to endplates, could not be exonerated. The
combination of different cell types in SVF with IVD com-
ponents hypothetically might have led to another potential
causative mechanism. Studies into the pathogenesis behind
haemophilic arthropathy have shown that iron from red
blood cells and cytokines from macrophages produce de-
structive oxygen metabolites that may harm the cartilage
[17]. This mechanism could also be responsible for the
adverse reactions we observed, as SVF contains both RBCs
and macrophages while the IVD resembles a cartilaginous
environment. Again, a combination of two or more different
described factors cannot be excluded as potential cause.
Finally, we want to note the distinct difference between
the studies with chemical degeneration using the enzyme
CABC and the partial nucleotomy model. While the CABC
model was used to induce a slow, mild degeneration
over 3 months, the nucleotomy model originally aimed to
mimic herniation, after which the discs were left to recover
for 6 weeks. In the discs that had received nucleotomy, no
adverse effects were observed after SVF injection, whereas
the chemically degenerated discs were severely damaged
by SVF. This difference could be explained by a difference
in the surrounding tissue reaction between surgical damage
and chemically induced disc degeneration. Whereas CABC
causes a catabolic degenerative cascade, it could be
speculated that mechanically damaged tissue after surgery
has a larger tendency to recover. This anabolic state might
benefit the reaction to injected agents, such as SVF, while a
catabolic state is more likely to respond adversely. This
could be an important clue for any future studies using
intradiscal cell injections. However, we re-emphasise here
that healthy discs also reacted adversely to SVF injection,
which points at a mechanism that is independent of the way
that discs were degenerated in the model.
Some limitations can be identified with regard to the
aforementioned studies. First of all, the collagenase en-
zyme used in study 3 (CelaseTM) is slightly different from
that of the first two goat studies. This might result in ob-
taining different SVF preparation with respect to the rela-
tive ratios between the ASCs and other cell types. In this
regard, it is important to mention that the ASC percentages
in the SVF as determined in the CFU-F assays were ex-
tremely low for the perirenal SVF preparations, and far
lower than those obtained previously with Liberase
Blendzyme III enzyme from Roche. Apparently, digestion
conditions vary for the two sources, since Celase appeared
equally effective for subcutaneous tissue when compared
with Liberase (own data). Although these studies were
limited by small sample sizes, due to the low number of
disc levels per treatment modality, the risks of SVF in-
jection into the IVD have been clearly established after
four consecutive large animal studies.
Conclusions
In our studies, we observed a consistent, severe inflam-
matory response after the injection of SVF into both
chemically degenerated and healthy goat IVDs, for which
no definite explanation could be identified. Nevertheless,
we conclude that injecting a heterogeneous mixture of cells
into a healthy or degenerated IVD bears a risk for severe
adverse effects. As the intervertebral disc is the largest
avascular organ in the body, it can easily turn into a cell-
hostile environment, as opposed to other well-vascularised
tissues that have proven a safe platform for SVF therapy.
Therefore, based on our observations in the goat disc de-
generation model, until the cause of these adverse effects is
elucidated, SVF injections into the IVD may not be ready
for application in clinical practice.
Fig. 4 a Macroscopic appearance of Fig. 3a, showing formation of
osteophytes starting a bony bridge anterior of the affected IVD.
b Macroscopic appearance of Fig. 3b, showing infiltration and
destruction of the bony endplates with a complete loss of normal
morphology
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